dr. yvonne greenstreet, ceo, alnylam
Published 2 years ago • 1.1K plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
3:26
first approved treatment using rnai – alnylam pharmaceuticals’ and bio chair john maraganore
-
2:19
get to know alnylam - the leader in rnai therapeutics
-
1:05
alnylam pharma and the science of rnai
-
2:20
the pioneers - developing a new class of medicines
-
1:27
conserving energy with als
-
7:18
researchers say they are close to reversing aging
-
4:51
john maraganore, ph.d., chief executive officer, alnylam pharmaceuticals, inc. at bio 2017
-
15:55
american gene technologies
-
28:08
a view into investing with technologists, biotech venture capitalists and biopharma innovators
-
14:05
viralgen vector core
-
0:56
lmna dysfunction and alzheimer’s disease
-
12:21
rejuvinate bio
-
1:29
how alnylam works with patient advocacy groups
-
41:49
clinical questions to drive the enterprise
-
13:58
vineti
-
14:49
mana bio
-
45:57
m. soller - elav-regulated rna processing in synaptic plasticit
-
2:45
what can the field learn from the covid-19 pandemic?
-
1:57
anti-hmgb1 agents for the treatment of alzheimer’s disease
-
26:38
2022 als one research symposium: brainstorm-cell therapeutics/nurown
-
1:00
alliance for aging research on patient treatment responses